Business Wire

MITSUBISHI-CHEMICAL-HLDG

Share
Mitsubishi Chemical Holdings Corporation: Notice Regarding Change in Representative Corporate Executive Officers

Mitsubishi Chemical Holdings Corporation (“MCHC”) (TOKYO: 4188) announced that, at the meeting of its Board of Directors held today, it resolved change of representative corporate executive officers as outlined below.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022006285/en/

1. Change in Representative Corporate Executive Officers

(Appointed)

Name:

Jean-Marc Gilson

 

Title:

Representative Corporate Executive Officer

 

 

President and Chief Executive Officer

 

 

(Retiring)

Name:

Hitoshi Ochi

 

Title:

Representative Corporate Executive Officer

 

 

President and Chief Executive Officer

2. Biographical Sketch of New Representative Corporate Executive Officer

Refer to the appendix

3. Scheduled Date of Appointment

April 1, 2021

4. Reason for the Change

MCHC converted to a company with a nominating committee, etc. in June 2015. Since then, the Nominating Committee has carried out preparations to properly conduct nominations, taking into account the period covered by the medium-term management plan and other factors. Representative Corporate Executive Officer, President and CEO, Hitoshi Ochi, has recently expressed his intent to retire at the end of the current fiscal year that coincides with the conclusion of the current medium-term management plan, where the fortification of its business infrastructure has been achieved to a meaningful degree. Therefore, the Nominating Committee explored and selected specific candidates of his successor.

The Nominating Committee set the following criteria for the next Representative Corporate Executive Officer, President and CEO. The individual had to be able to execute the following initiatives reflecting our Group Philosophy, KAITEKI.

(1)

Able to build a strategic vision and branding strategy, foreseeing the post-COVID 19 world, that integrates the healthcare business, including biochemicals and life science, with the high-value added chemicals business based on the high-performance products

(2)

Capable of improving corporate value particularly from the perspective of shareholders and investors

(3)

Able to decisively implement portfolio transformation through strong leadership

The Nominating Committee searched globally for suitable candidates, both inside and outside the company. It conducted multifaceted evaluations, including interviews with candidates and gathered references from related parties on the past performance of potential candidates. The Nominating Committee ultimately nominated Jean-Marc Gilson based on which MCHC, at the meeting of Board of Directors today, adopted the resolution to select him as the next Representative Corporate Executive Officer, President and CEO.

Jean-Marc Gilson has demonstrated leadership in the positions of president or chief executive in charge of business operations at various US and European chemical companies. This includes Executive Vice President, Specialty Chemicals Business at Dow Corning. Then he served as CEO at Avantor Performance Materials, which was selected by New Mountain Capital, a private equity fund, as their first investment in the chemicals sector. After this, at the request of New Mountain Capital, he served as COO at NuSil Technology. At present, he serves as CEO of Roquette, headquartered in France.

Jean-Marc Gilson possesses a global outlook in the fields of specialty chemicals and life science. In his previous experiences he worked at, Gilson built a proven track record for decisively executing portfolio transformation. In addition, he fully understands how correctly establishing strategies and clearly disseminating these strategies to all stakeholders contributes to the improvement of corporate value.

Given his performance, competencies and enthusiasm to lead the company, we determined that Jean-Marc Gilson is the optimal choice to lead MCHC realizing our vision of sustainable growth by accelerating our portfolio transformation and globally undertaking initiatives to solve social issues based on the Group Philosophy, KAITEKI.

Appendix

Biographical Sketch

Name:

Jean-Marc Gilson

Date of Birth:

December 16, 1963

Place of Birth:

Belgium

 

 

Professional Experience

1989

Joined Dow Corning

2005

Corporate Vice President & General Manager of Specialty Chemicals Business, President Asian Area, Dow Corning

Shareholder Representative Director, Dow Corning Toray

2009

Executive Vice President & General Manager of Specialty Chemicals Business,

Dow Corning

2011

Chief Executive Officer, Avantor Performance Materials

2012

Vice-Chairman & Chief Operating Officer, NuSil Technology

2014

Chief Executive Officer, Roquette

2021

To be appointed Representative Corporate Executive Officer,

President and Chief Executive Officer,

Mitsubishi Chemical Holdings Corporation

Number of shares held: N/A

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release

Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release

Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release

New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye